Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Short-term Investments (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Short-term Investments for 9 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 88.02% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Dec 2025, down 88.02%, and an annual FY2025 reading of $5.0 million, down 88.02% over the prior year.
  • Short-term Investments was $5.0 million for Q4 2025 at VYNE Therapeutics, down from $17.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $66.9 million in Q1 2024 and bottomed at $1.0 million in Q1 2021.
  • Average Short-term Investments over 4 years is $35.5 million, with a median of $41.6 million recorded in 2024.
  • The sharpest move saw Short-term Investments soared 143.94% in 2021, then plummeted 88.02% in 2025.
  • Year by year, Short-term Investments stood at $1.0 million in 2021, then skyrocketed by 5998.64% to $62.6 million in 2023, then crashed by 33.6% to $41.6 million in 2024, then tumbled by 88.02% to $5.0 million in 2025.
  • Business Quant data shows Short-term Investments for VYNE at $5.0 million in Q4 2025, $17.6 million in Q2 2025, and $22.1 million in Q1 2025.